Skip to main navigation Skip to search Skip to main content

Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis

Kevin Berrios, Alexandra Burum, Eunae Jeong, Lixian Zhong

Research output: Contribution to journal › Article › peer-review

1   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Agricultural and Biological Sciences